Market Research Report
Acute Coronary Syndrome: Competitive Landscape to 2026
|Published by||GlobalData||Product code||673447|
|Published||Content info||49 Pages
Delivery time: 1-2 business days
|Acute Coronary Syndrome: Competitive Landscape to 2026|
|Published: June 30, 2018||Content info: 49 Pages||
Acute coronary syndrome (ACS) refers to a spectrum of myocardial ischemic states caused by the disruption of atherosclerotic plaques in the coronary arteries. The syndrome is precipitated by coronary artery occlusion (stenosis), which results in ischemia and myocardial necrosis. The development of ACS is heavily influenced by diet and lifestyle, and can manifest as myocardial infarction (MI) or unstable angina (UA).
This report provides an assessment of the pipeline, clinical, and commercial landscape of ACS. Overall, GlobalData expects new drug approvals to drive ACS market growth over the next decade (2016-2026).
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -